IN THE DISTRICT COURT OF CLEVELAND COUNTY
STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel., MIKE HUNTER, ATTORNEY GENERAL OF OKLAHOMA, Plaintiff, v. PURDUE PHARMA L.P., et al., Defendants.	)	Case No. CJ-2017-816 Honorable Thad Balkman

JANSSEN DEFENDANTS' ADOPTION AND JOINDER TO THE PURDUE DEFENDANTS' OBJECTIONS TO THE SPECIAL DISCOVERY MASTER'S ORDER OVERRULING OBJECTIONS TO THE STATE'S CORPORATE REPRESENTATIVE TOPICS

Defendants Johnson & Johnson, Inc., Janssen Pharmaceuticals, Inc., Ortho-McNeil Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc. (collectively "Janssen") respectfully submit this Adoption[1] and Joinder to Purdue's Objections to the Special Discovery Master's Order Overruling Purdue's Objections to the State's Corporate Representative Topics (hereinafter "Purdue's Objections"), filed by Purdue Pharma, L.P., Purdue Pharma, Inc., and The Purdue Frederick Company (collectively "Purdue") on November 26, 2018.

On November 17, 2018, the Discovery Master ruled that it would allow the State to unilaterally define the scope of depositions noticed pursuant to Okla. Stat. tit. 12, § 3230(C)(5), without any judicial check to ensure those topics requested by the State are proportional and reasonably calculated to lead to the discovery of admissible evidence. Janssen joins Purdue in respectfully objecting to the Discovery Master's blanket ruling dismissing all existing or future

[1] Okla. Stat. tit, 12, § 2010(C).

objections to the scope of the State's corporate representative deposition discovery, and requests this Court engage in a fair and individualized review of Defendants objections and rule to limit the scope of the State's discovery as appropriate.

Janssen initially offered witnesses to cover 29 of the State's 41 noticed deposition topics over seven deposition days and proposed written responses for another eight topics. Janssen also served objections and offered to meet and confer with the State on the scope of the topics objectionable in whole or in part. *See* Letter from S. Brody to D Pate, 9/10/18 (attached as Exhibit A); Objections (attached as Exhibit B). The parties held an initial meet and confer teleconference on September 21, 2018, focused on scheduling, but the State ultimately rejected all of the proposed dates except one. And rather than working with Janssen to schedule dates and resolve objections through the meet and confer process, the State then filed a motion that asked the Discovery Master to rule in advance that the State would be allowed up to 102 hours for the noticed topics. The State did not seek to resolve Janssen's objections.

Following a hearing on the motion, the Discovery Master ordered the State to specifically define its topics. On October 29, the State simply restated the broad topics it had previously identified. *See* Email from D. Pate to S. Brody, 10/29/18, with attachments (attached as Exhibit C). Janssen submitted its response to the State on November 9, 2018 (noting in the process that the State had failed to comply with the Discovery Master's order that it specifically define its topics). *See* Letter from T. Allan to D. Pate, 11/9/18 (attached as Exhibit D).

The Discovery Master held an emergency Saturday morning hearing on November 17, 2018, to address deposition-related issues. At that hearing, despite having never seen Janssen's objections, the Discovery Master issued a blanket ruling that purported to overrule, sight unseen, all Defendants' objections and grant the State permission to conduct depositions on every single

one of the State's chosen topics, as drafted, and without limitation.[2] *See* Purdue Objections at 5-6; Nov. 17, 2018 Hr. Tr. at 31:14, 31:20-22, 32:6-7, 32:24-33:1.

For all the reasons set out in Purdue's Objections, which are equally applicable to Janssen, Janssen adopts and joins Purdue's objection and request for relief from the Discovery Master's ruling.

Dated: November 26, 2018.

Respectfully submitted,

By: _____

Benjamin H. Odom, OBA No. 10917
John H. Sparks, OBA No. 15661
Michael W. Ridgeway, OBA No. 15657
David L. Kinney, OBA No. 10875
ODOM, SPARKS & JONES, PLLC
Suite 140
HiPoint Office Building
2500 McGee Drive
Norman, OK 73072
Telephone: (405) 701-1863
Facsimile: (405) 310-5394
Email: odomb@odomsparks.com
Email: sparksj@odomsparks.com
Email: ridgewaym@odomsparks.com
Email: kinneyd@odomsparks.com

Larry D. Ottaway, OBA No. 6816
Amy Sherry Fischer, OBA No. 16651
FOLIART, HUFF, OTTAWAY & BOTTOM
12th Floor
201 Robert S. Kerr Avenue
Oklahoma City, OK 73102
Telephone: (405) 232-4633
Facsimile: (405) 232-3462
Email: larryottaway@oklahomacounsel.com
Email: amyfischer@oklahomacounsel.com

[2] In October, the State served an additional three deposition topics on Janssen. Janssen also objected to these topics on 10/4/18 and 10/11/18. Although those topics and objections were not at issue in the State's Motion to Compel, Janssen requests that any relief apply to all of the Janssen's objections to corporate representative topics.

Of Counsel:

Charles C. Lifland
Jennifer D. Cardelús
Wallace Moore Allan
Sabrina H. Strong
Houman Eshan
Esteban Rodriguez
O'MELVENY & MYERS, LLP
400 S. Hope Street
Los Angeles, CA 90071
Telephone: (213) 430-6000
Facsimile: (213) 430-6407
Email: clifland@omm.com
Email: jcardelus@omm.com
Email: tallan@omm.com
Email: sstrong@omm.com
Email: heshan@omm.com
Email: erodriguez2@omm.com

Amy R. Lucas
Lauren S. Rakow
O'MELVENY & MYERS, LLP
8th Floor
1999 Avenue of the Stars
Los Angeles, CA 90067
Telephone: (310) 553-6700
Facsimile: (310) 246-6779
Email: alucas@omm.com
Email: lrakow@omm.com

Stephen D. Brody
David Roberts
O'MELVENY & MYERS, LLP
1625 Eye Street NW
Washington, DC 20006
Telephone: (202) 383-5300
Facsimile: (202) 383-5414
Email: sbrody@omm.com
Email: droberts2@omm.com

Daniel J. Franklin
Ross B. Galin
Desirae Krislie Cubero Tongco
O'MELVENY & MYERS, LLP
7 Times Square
New York, NY 10036
Telephone: (212) 326-2000
Facsimile: (212) 326-2061
Email: dfranklin@omm.com
Email: rgalin@omm.com
Email: dtongco@omm.com

COUNSEL FOR DEFENDANTS JANSSEN PHARMACEUTICALS, INC., JOHNSON & JOHNSON, JANSSEN PHARMACEUTICA, INC. N/K/A JANSSEN PHARMACEUTICALS, INC., AND ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. N/K/A/ JANSSEN PHARMACEUTICALS, INC.

CERTIFICATE OF MAILING

Pursuant to Okla. Stat. tit. 12, § 2005(D), and agreement of the parties this is to certify on November 26, 2018, a true and correct copy of the above and foregoing has been served via electronic mail, to the following:

Mike Hunter
ATTORNEY GENERAL FOR
THE STATE OF OKLAHOMA
Abby Dillsaver
Ethan Shaner
GENERAL COUNSEL TO
THE ATTORNEY GENERAL
313 NE 21st
Oklahoma City, OK 73105
Telephone: (405)521-3921
Facsimile: (405) 521-6246
Email: mike.hunter@oag.ok.gov
Email: abby.dillsaver@oag.ok.gov
Email: ethan.shaner@oag.ok.gov

Michael Burrage
Reggie Whitten
J. Revell Parrish
WHITTEN BURRAGE
Suite 300
512 North Broadway Avenue
Oklahoma City, OK 73102
Telephone: (405) 516-7800
Facsimile: (405) 516-7859
Email: mburrage@whittenburragelaw.com
Email: rwhitten@whittenburragelaw.com
Email: rparrish@whittenburragelaw.com

Bradley Beckworth
Jeffrey Angelovich
Lloyd Nolan Duck, III
Andrew Pate
Lisa Baldwin
Brooke A. Churchman
NIX, PATTERSON, LLP
Suite 200
512 North Broadway Avenue
Oklahoma City, OK 73102
Telephone: (405) 516-7800
Facsimile: (405) 516-7859
Email: bbeckworth@nixlaw.com
Email: jangelovich@nixlaw.com
Email: tduck@nixlaw.com
Email: dpate@nixlaw.com
Email: lbaldwin@nixlaw.com
Email: bchurchman@nixlaw.com

Glenn Coffee
GLENN COFFEE & ASSOCIATES, PLLC
915 North Robinson Avenue
Oklahoma City, OK 73102
Telephone: (405) 601-1616
Email: gcoffee@glenncoffee.com

ATTORNEYS FOR PLAINTIFF

Sanford C. Coats
Joshua D. Burns
CROWE & DUNLEVY, PC
Suite 100
Braniff Building
324 North Robinson Avenue
Oklahoma City, OK 73102
Telephone: (405) 235-7700
Facsimile: (405) 272-5269
Email: sandy.coats@crowedunlevy.com
Email: joshua.burns@crowedunlevy.com

Of Counsel:

Sheila Birnbaum
Mark S. Cheffo
Hayden A. Coleman
Paul A. LaFata
Jonathan S. Tam
Lindsay N. Zanello
Bert L. Wolff
DECHERT, LLP
Three Bryant Park
1095 Avenue of Americas
New York, NY 10036-6797
Telephone: (212) 698-3500
Facsimile: (212) 698-3599
Email: sheila.birnbaum@dechert.com
Email: mark.cheffo@dechert.com
Email: hayden.coleman@dechert.com
Email: paul.lafata@dechert.com
Email: jonathan.tam@dechert.com
Email: lindsay.zanello@dechert.com
Email: bert.wolff@dechert.com

Benjamin F. McAnaney
Dechert, LLP
2929 Arch Street
Philadelphia, PA 19104
Telephone: (215) 994-4000
Facsimile: (215) 655-2043
Email: benjamin.mcananey@dechert.com

Erik W. Snapp
DECHERT, LLP
Suite 3400
35 West Wacker Drive
Chicago, IL 60601
Telephone: (212)849-7000
Facsimile: (212) 849-7100
Email: erik.snapp@dechert.com

Robert S. Hoff
WIGGIN & DANA, LLP
265 Church Street
New Haven, CT 06510
Telephone: (203) 498-4400
Facsimile: (203) 363-7676
Email: rhoff@wiggin.com

Britta E. Stanton
John D. Volney
John T. Cox, III
Eric W. Pinker
Jared D. Eisenberg
Jervonne D. Newsome
LYNN PINKER COX & HURST, LLP
Suite 2700
2100 Ross Avenue
Dallas, TX 75201
Telephone: (214) 981-3800
Facsimile: (214) 981-3839
Email: bstanton@lynnllp.com
Email: jvolney@lynnllp.com
Email: tcox@lynnllp.com
Email: epinker@lynnllp.com
Email: jeisenberg@lynnllp.com
Email: jnewsome@lynnllp.com

ATTORNEYS FOR DEFENDANTS PURDUE PHARMA, LP, PURDUE PHARMA, INC., AND THE PURDUE FREDERICK COMPANY, INC.

Robert G. McCampbell
Travis V. Jett
Ashley E. Quinn
Nicholas V. Merkley
GABLEGOTWALS
15th Floor
One Leadership Square
211 North Robinson
Oklahoma City, OK 73102-7255
Telephone: (405) 235-5567
Email: rmccampbell@gablelaw.com
Email: tjett@gablelaw.com
Email: aquinn@gablelaw.com
Email: nmerkley@gablelaw.com

Of Counsel:

Steven A. Reed
Rebecca J. Hillyer
MORGAN, LEWIS & BOCKIUS, LLP
1701 Market Street
Philadelphia, PA 19103-2321
Telephone: (215) 963-5000
Email: steven.reed@morganlewis.com
Email: rebecca.hillyer@morganlewis.com

Harvey Bartle, IV
Mark A. Fiore
MORGAN, LEWIS& BOCKIUS, LLP
502 Carnegie Center
Princeton, NJ 08540-6241
Telephone: (609) 919-6600
Email: harvey.bartle@morganlewis.com
Email: mark.fiore@morganlewis.com

Brian M. Ercole
MORGAN, LEWIS & BOCKIUS, LLP
Suite 5300
200 South Biscayne Boulevard
Miami, FL 33131
Email: brian.ercole@morganlewis.com

ATTORNEYS FOR DEFENDANTS CEPHALON, INC., TECA PHARMACEUTICALS USA, INC., WATSON LABORATORIES, INC., ACTAVIS, LLC, AND ACTAVIS PHARMA, INC. F/K/A WATSON PHARMA, INC.



John H. Sparks

COUNSEL FOR DEFENDANTS JANSSEN PHARMACEUTICALS, INC., JOHNSON & JOHNSON, JANSSEN PHARMACEUTICA, INC. N/K/A JANSSEN PHARMACEUTICALS, INC., AND ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. N/K/A/ JANSSEN PHARMACEUTICALS, INC.

EXHIBIT A

O'Melveny & Myers LLP
1625 Eye Street, NW
Washington, DC 20006-4061

T: +1 202 383 5300
F: +1 202 383 5414
omm.com

File Number:
427,892-297

September 10, 2018

Steve Brody
D: +1 202 383 5167
sbrody@omm.com

VIA E-MAIL

Reggie Whitten
Michael Burrage
WHITTEN BURRAGE
512 N. Broadway Avenue, Suite 300
Oklahoma City, OK 73102

Re: ***State of Oklahoma v. Purdue Pharma L.P. et al., No. CJ-2017-816***

Dear Reggie and Mike:

We are serving objections today for the 41 corporate representative notices the State served on Janssen on August 8, 2018. These notices would require Janssen's counsel and witnesses to appear in Oklahoma on 41 separate days between September 21, 2018 and December 5, 2018. We are willing to meet and confer on these objections.

Subject to our objections, we will offer a witness to testify to the following topics on October 10, and, if necessary, October 11, 2018, in Oklahoma City.

- Your involvement with, and contributions to, non-profit organizations and professional societies, including the Front Groups.
- Your involvement with, and contributions to, KOLs regarding opioids and/or pain treatment
- Your use of branded marketing for opioids nationally and in Oklahoma, including the scope, strategy, purpose and goals with respect to such branded marketing.
- Your use of unbranded marketing for opioids nationally and in Oklahoma, including the scope, strategy, purpose and goals with respect to such unbranded marketing.
- Your use of continuing medical education regarding opioids nationally and in Oklahoma, including the scope, strategy, purpose and goals with respect to such continuing medical education.
- The scope, strategy, purpose, and goals for Your opioids sales forces, including without limitation: training policies and practices; sales tactics; compensation structures; incentive programs; award programs; sales quotas; methods for

assigning sales representatives to particular regions; facilities and/or physicians; and Your use of such sales forces in Oklahoma.

- Your practices and processes for identifying and prioritizing physicians to detail.
- Your research of Oklahoma Healthcare Professionals' and/or pharmacies' opioid prescribing habits, history, trends, sales, practices and/or abuse and diversion of opioids.
- Your use of 'do not call' lists or any similar list of prescribers that your sales representatives do not contact.
- Your efforts to identify high-prescribing health care providers in the State of Oklahoma.
- Your efforts to identify low-prescribing health care providers in the State of Oklahoma.
- Your role, influence, or support for any campaign or movement to declare pain as the "Fifth Vital Sign."
- Your use of medical education communication companies (MECCs) regarding opioids and/or pain management marketing.
- Your use of speakers' bureaus, advisory boards, or other similar programs regarding opioids and/or pain management marketing.
- Your use of medical liaisons to communicate with Healthcare Professionals, KOLs, and/or Front Groups regarding opioids and/or pain treatment.
- Your use of data provided by IMS, IQVIA or any similar data service for purposes of marketing and/or sales strategies.
- Your sales projections and/or research related to the amount of reimbursement for Your opioids prescriptions that would be paid by Medicare and/or Oklahoma's Medicaid Program.
- Your efforts and actions, both internally and in conjunction with third parties, to obtain and/or increase coverage and/or reimbursement of their opioids by public payers, including SoonerCare.

Additionally, we will offer a second witness to testify to the following topics on October 23, and if necessary, October 24, 2018, in Oklahoma City.

- Research conducted, funded, directed and/or influenced by You, in whole or in part, related to opioid risks and/or efficacy.

- Your scientific support for Your marketing statements and representations regarding the risks and benefits of opioids.
- Your research conducted, funded, directed and/or influenced, in whole or in part, related to pseudoaddiction.
- Your scientific support for Your marketing statements and representations regarding pseudoaddiction.
- Your use and/or establishment of any opioid abuse and diversion program You established and implemented to identify Healthcare Professionals' and/or pharmacies' potential abuse or diversion of opioids.
- Your use of clinical trial companies regarding opioids and/or pain management.
- Clinical trials funded, sponsored, and/or conducted by You regarding opioids and/or pain management.
- Policies, practices, and procedures regarding complaints You received related to addiction or abuse of Your opioids in Oklahoma.
- Your actions and/or efforts in response to the FDA's September 10, 2013 response to the PROP Petition from July 25, 2012.

We trust this will provide the State with enough time to prepare for these depositions despite the fact that certain of the topics were originally noticed for later dates. Please confirm whether these dates will work for the State's counsel. We expect to follow up shortly and identify dates certain for topics 33 and 34 during the week of November 5 and for topics 39 and 41 during the week of November 12.

Additionally, as set forth in our objections, there are two topics for which we object to providing a witness:

- The amount of revenue and profits earned by You attributable to and/or derived from the prescription of opioids by any Oklahoma doctor criminally investigated, charged, indicted, and/or prosecuted for prescribing practices related to opioids. For purposes of this topic, "prosecution" includes any administrative proceeding.
- The factual bases supporting Your defenses to Plaintiff's claims as set forth in Your Answer.

We also believe some of the noticed topics are more appropriately handled by written responses and we have identified those topics specifically in our written objections. We are open to meet and confer on both of these issues.

Thank you for your attention to the foregoing.

Sincerely,



Stephen D. Brody
for O'MELVENY & MYERS LLP

cc: Counsel of Record

EXHIBIT B

IN THE DISTRICT COURT OF CLEVELAND COUNTY
STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel. MIKE HUNTER, ATTORNEY GENERAL OF OKLAHOMA,	
Plaintiff,	**Case No. CJ-2017-816**
VS.	**Judge Thad Balkman**
PURDUE PHARMA, L.P., ET AL.	**Special Master: William Hetherington**
Defendants.	

DEFENDANTS JOHNSON & JOHNSON, JANSSEN PHARMACEUTICALS, INC., ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC., AND JANSSEN PHARMACEUTICA, INC.'S OMNIBUS OBJECTIONS TO TOPICS IN PLAINTIFF'S NOTICES OF VIDEOTAPED 3230(C)(5) DEPOSITIONS

Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc. (collectively, "Janssen") provide an omnibus response with the following objections to Plaintiff's amended notices of videotaped 3230(C)(5) depositions to Janssen, noticed for various dates from September 21, 2018 through December 5, 2018 (the "Notices").[1]

OFFER TO MEET AND CONFER

Janssen offers to meet and confer in good faith concerning its objections prior to filing for a protective order to give Plaintiff an opportunity to appropriately limit the scope of the topics in the Notices.

[1] Specifically, the Notices are noticed for the following dates this year: September 21, 24, 25, 27, and 28; October 1, 2, 3, 4, 5, 9, 10, 15, 16, 17, 19, 30, and 31; November 1, 5, 6, 7, 8, 14, 15, 19, 20, 26, 27, 28, and 29; and December 3, 4, and 5.

GENERAL OBJECTIONS

1. To the extent that Janssen designates witnesses to testify and provides testimony in response to the Notices, it does so solely for the purpose of the above-captioned case, unless Janssen cross-notices the deposition for another proceeding. Moreover, by providing such testimony and responding to the Notices, Janssen does not waive any objections that it may have to the admission into evidence of any testimony provided or these responses on any applicable grounds.

2. Janssen objects to the Notices and the topics in the Notices to the extent that the topics fail to identify the requested subject matter with reasonable particularity; are unduly burdensome, oppressive, overly broad, ambiguous, confusing, vague, or duplicative or unreasonably cumulative of other discovery in this proceeding; seek information that is available through other types of discovery that are less burdensome and more appropriate; or call for Janssen to draw a legal conclusion and/or provide expert opinions in order to respond.

3. Janssen objects to the Notices, including but not limited to the instructions regarding the purported "affirmative duty" to prepare on the grounds and to the extent that they purport to impose obligations or burdens on Janssen that go beyond those imposed by Oklahoma Rule of Civil Procedure 12-3230 and the Local Rules of the District Court of Cleveland County. Janssen will comply with the Discovery Rules, but assumes no further obligations in responding to these Notices and rejects any attempt to impose additional obligations and repercussions.

4. Janssen objects to the Notices to the extent that they seek discovery that is not relevant to the parties' claims and defenses or not proportional to the needs of the case,

considering the importance of the issues at stake in the action, the amount in controversy, the parties' relative access to relevant information, the parties' resources, the importance of the discovery in resolving the issues, and whether the burden or expense of the proposed discovery outweighs its likely benefit, and that otherwise goes beyond the scope of permissible discovery at this stage of this proceeding.

5. Janssen objects to the Notices to the extent that that they seek information that is protected from disclosure by the attorney-client privilege, work product doctrine, joint defense privilege, common interest privilege, or any other applicable privilege or protection ("privileged information"). The inadvertent disclosure of privileged information through testimony provided in response to the Notices shall not be deemed a waiver of any privilege as to the privileged information inadvertently disclosed or any other information or documents relating to the subject matter of any inadvertently disclosed privileged information.

6. Janssen objects to the Notices to the extent that any topic or instruction seeks disclosure of information protected by any confidentiality obligation owed to a third party. Janssen will not disclose such information absent notice to and, if required, consent of the third party or entry of a court order compelling production.

7. Janssen objects to the Notices to the extent they call for information being provided or otherwise available to Plaintiff through produced documents or discovery, including data and information provided by Janssen.

8. Janssen objects to the Notices, the instructions used in the Notices, and the topics in the Notices to the extent that they assume facts and events or include characterizations that are assumed to be accurate, and/or contain legal conclusions. By

providing responses to these Notices and testimony on the topics in the Notices, Janssen does not admit or concede that any assumed fact, event, characterization, or legal conclusion is correct or accurate. Janssen expressly reserves the right to contest any and all assumed facts, events, characterizations, and legal conclusions.

9. Janssen objects to each topic or instruction that purports to require that Janssen identify and provide discovery with regard to "each," "all," "any" or similar all-encompassing terms, on the grounds that such topics and instructions are not stated with reasonable particularity, are overly broad and unduly burdensome, and seek discovery that is not relevant to the parties' claims and defenses, not proportional to the needs of the case, and beyond the scope of permissible discovery, particularly at this stage of the proceeding.

10. Janssen objects to each topic to the extent that it seeks premature expert discovery or disclosure of expert opinions and goes beyond the scope of permissible expert discovery under the Discovery Rules. Janssen will provide expert discovery and disclosures on the dates set by the Court in compliance with the discovery rules, but assumes no further obligation in responding to these requests.

11. Unless otherwise indicated in writing by Janssen's counsel, Janssen's witnesses are authorized to testify in a Rule 3230(C)(5) capacity only to the extent that Janssen has designated them to do so in these responses and subject to the objections lodged by Janssen. Janssen reserves the right to supplement or correct any Rule 3230(C)(5) testimony as appropriate.

12. Janssen reserves all other objections and the right to correct or supplement these objections and responses. Janssen's agreement to produce a witness on a given topic shall not imply that responsive information exists within Janssen's possession, custody, or

control, or constitute an admission or acknowledgment as to the relevance, admissibility, or authenticity of any information or as to the truth of any allegation or assumption contained in the Notices.

SPECIFIC RESPONSES AND OBJECTIONS

TOPIC NO. 1:

Your involvement with, and contributions to, non-profit organizations and professional societies, including the Front Groups.

RESPONSE NO. 1:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen further objects to the term "Front Groups" as vague and ambiguous. Janssen further objects to this term on the grounds that it is inappropriately pejorative and inaccurately represents Janssen's relationships with independent third-party organizations. Janssen further objects to the use of the term "Front Groups" because it is overly broad and unduly burdens Janssen to the extent that it includes organizations that did not make any alleged representations regarding the opioid products at issue to Oklahoma patients or prescribers. Subject to and without waiving the foregoing objections, Janssen will designate a witness to testify regarding relevant, nonprivileged information relating to the ten organizations incorporated in Plaintiff's definition of the term Front Groups in Plaintiff's First Set of Interrogatories.

TOPIC NO. 2:

Your involvement with, and contributions to, KOLs regarding opioids and/or pain treatment.

RESPONSE NO. 2:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen further objects to the term "KOLs" on the grounds that it is vague and ambiguous. Janssen further objects to the term because it seeks information irrelevant to the case, is overly broad, and imposes undue burden and expense on Janssen in relation to the needs of the case to the extent that the term includes individuals who did not make any alleged representations regarding the opioid products at issue to Oklahoma patients or prescribers. Subject to and without waiving the foregoing objections, Janssen will designate a witness to testify regarding relevant, nonprivileged information regarding its involvement with or contributions to the eight healthcare providers incorporated in Plaintiff's definition of the term KOL in Plaintiff's First Set of Interrogatories, as related to opioids or pain treatment.

TOPIC NO. 3:

Your use of branded marketing for opioids nationally and in Oklahoma, including the scope, strategy, purpose and goals with respect to such branded marketing.

RESPONSE NO. 3:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects to the extent that the topic seeks information that is unrelated to the claims and defenses in this litigation including to the extent it encompasses matters relating to "marketing for opioids nationally." The topic is overly broad and unduly burdensome. Janssen also objects that "use" and "branded marketing" are vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify regarding relevant, nonprivileged information about branded marketing in Oklahoma for the Janssen opioid products mentioned in Plaintiff's Complaint: Nucynta IR, Nucynta ER, and Duragesic (hereinafter, "Janssen's Opioid

Products"). To the extent Janssen utilized national branded marketing for its Opioid Products in Oklahoma, it will be included.

TOPIC NO. 4:

Your use of unbranded marketing for opioids nationally and in Oklahoma, including the scope, strategy, purpose and goals with respect to such unbranded marketing.

RESPONSE NO. 4:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects to the extent that the topic seeks information that is unrelated to the claims and defenses in this litigation including to the extent it encompasses matters relating to "marketing for opioids nationally." The topic is overly broad and unduly burdensome. Janssen also objects that "use" and "unbranded marketing" are vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify regarding relevant, nonprivileged information about unbranded marketing for Janssen's Opioid Products in Oklahoma (to the extent national branded marketing was utilized in Oklahoma, it will be included).

TOPIC NO. 5:

Your use of continuing medical education regarding opioids nationally and in Oklahoma, including the scope, strategy, purpose and goals with respect to such continuing medical education.

RESPONSE NO. 5:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects to the extent that the topic seeks information that is unrelated to the claims and defenses in this litigation including to the extent it encompasses matters relating to "medical education regarding opioids nationally." The topic is overly broad and unduly burdensome.

Janssen also objects that "use" and "continuing medical education" are vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information about the education process regarding Janssen's Opioid Products throughout Oklahoma (to the extent national branded marketing was utilized in Oklahoma, it will be included).

TOPIC NO. 6:

Research conducted, funded, directed and/or influenced by You, in whole or in part, related to opioid risks and/or efficacy.

RESPONSE NO. 6:

Janssen objects to this topic on the grounds set forth in its General Objections. To the extent that Janssen has already provided documentary discovery responses related to Topic 6, Janssen objects. Janssen also objects to the extent that Topic 6 calls for information within the purview of expert testimony. Further, this topic is overly broad and unduly burdensome. As framed, it would require Janssen's witness to speak to all existing opioid studies and scientific research, regardless of whether Janssen sponsored it or received it, or whether it was submitted to the FDA in connection with the IND/NDAs for Janssen's Opioid Products. Janssen also objects that "directed and/or influenced by You" is vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information about Janssen's studies, scientific research, tests, trials or analysis of the safety and efficacy that Janssen submitted to the FDA in conjunction with the IND/NDAs of Janssen's Opioid Products.

TOPIC NO. 7:

Your scientific support for Your marketing statements and representations regarding the risks and benefits of opioids.

RESPONSE NO. 7:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen objects to the topic to the extent that it seeks information already provided in response to document requests and interrogatories. Further, Janssen objects to the extent that this topic seeks information that is in the purview of expert testimony. The topic is overly broad and unduly burdensome. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information submitted to the FDA in conjunction with the IND/NDAs of Janssen's Opioid Products that supports statements Janssen made to the FDA, medical professionals, patients, or the public regarding opioids.

TOPIC NO. 8:

Your research conducted, funded, directed and/or influenced, in whole or in part, related to pseudoaddiction.

RESPONSE NO. 8:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects to the extent that Topic No. 8 seeks information in the purview of expert testimony. Janssen further objects that "directed and/or influenced" are vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information submitted to the FDA in conjunction with the IND/NDAs of Janssen's Opioid Products that supports statements Janssen made to the FDA, medical professionals, patients, or the public regarding opioids

TOPIC NO. 9:

Your scientific support for Your marketing statements and representations regarding pseudoaddiction.

RESPONSE NO. 9:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects to the extent that Topic No. 9 seeks information in the purview of expert testimony. Janssen further objects that "pseudoaddiction" is vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information submitted to the FDA in conjunction with the IND/NDAs of Janssen's Opioid Products that supports statements Janssen made to the FDA, medical professionals, patients, or the public regarding opioids.

TOPIC NO. 10:

The scope, strategy, purpose, and goals for Your opioids sales forces, including without limitation: training policies and practices; sales tactics; compensation structures; incentive programs; award programs; sales quotas; methods for assigning sales representatives to particular regions; facilities and/or physicians; and Your use of such sales forces in Oklahoma.

RESPONSE NO. 10:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that the topic is overly broad, unduly burdensome, and fails to describe with reasonable particularity the matters to be examined. Janssen further objects to this topic on the ground that the terms "sales tactics" and "sales quotas" are vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information about Janssen's sales force detailing Janssen's Opioid Products in Oklahoma, including training policies and practices; sales strategies; compensation structures;

incentive programs; sales objectives or goals; methods for assigning sales representatives to particular regions; and facilities and/or physicians.

TOPIC NO. 11:

Your practices and processes for identifying and prioritizing physicians to detail.

RESPONSE NO. 11:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that the topic is overly broad, unduly burdensome, and fails to describe with reasonable particularity the matters to be examined. Janssen further objects that "practices and processes" is vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information about the process Janssen used to determine which medical professionals or offices sales representatives to contact regarding Janssen's Opioid Products in Oklahoma.

TOPIC NO. 12:

Your research of Oklahoma Healthcare Professionals' and/or pharmacies' opioid prescribing habits, history, trends, sales, practices and/or abuse and diversion of opioids.

RESPONSE NO. 12:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that the topic is overly broad, unduly burdensome, and fails to describe with reasonable particularity the matters to be examined. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information about any Janssen's process for determining Oklahoma Healthcare Professionals' and/or pharmacies' opioid prescribing habits, history, trends, sales, practices and/or abuse and diversion of opioids.

TOPIC NO. 13:

Your use and/or establishment of any opioid abuse and diversion program You established and implemented to identify Healthcare Professionals' and/or pharmacies' potential abuse or diversion of opioids.

RESPONSE NO. 13:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects to the extent that Topic No. 13 seeks information that is unrelated to the claims and defenses in this litigation, material subject to the attorney-client privilege or the work product doctrine, or information that is in the purview of expert testimony. Janssen further objects that "use" and "opioid abuse and diversion program" are vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information regarding Janssen's processes for identifying potential abuse or diversion of opioids in Oklahoma.

TOPIC NO. 14:

Your use of 'do not call' lists or any similar list of prescribers that your sales representatives do not contact.

RESPONSE NO. 14:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that the topic is overly broad, unduly burdensome, and fails to describe with reasonable particularity the matters to be examined. Janssen further objects that "'do not call' lists" and "similar list" are vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information about Janssen's processes for determining which medical

professionals or offices sales representatives would not contact regarding Janssen's Opioid Products in Oklahoma.

TOPIC NO. 15:

Your efforts to identify high-prescribing health care providers in the State of Oklahoma.

RESPONSE NO. 15:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that the topic is overly broad, unduly burdensome, and fails to describe with reasonable particularity the matters to be examined. Janssen further objects that "high-prescribing health care providers" is vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information about Janssen's processes for determining which medical professionals or offices sales representatives would contact regarding Janssen's Opioid Products in Oklahoma.

TOPIC NO. 16:

Your efforts to identify low-prescribing health care providers in the State of Oklahoma.

RESPONSE NO. 16:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that the topic is overly broad, unduly burdensome, and fails to describe with reasonable particularity the matters to be examined. Janssen further objects that "low-prescribing health care providers" is vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information about Janssen's processes for determining which medical professionals or offices sales representatives would contact regarding Janssen's Opioid Products in Oklahoma.

TOPIC NO. 17:

Amounts spent by You on advertising and marketing related to opioids.

RESPONSE NO. 17:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that Topic No. 17 is an interrogatory-style topic. Janssen further objects that the topic is overly broad and unduly burdensome. Subject to and without waiving the foregoing objections, Janssen proposes to provide a written response to this topic regarding the amount spent by Janssen on advertising and marketing relating to Janssen's Opioid Products, in lieu of deposition testimony. Janssen will make itself available to meet and confer with regard to this proposal.

TOPIC NO. 18:

Amounts spent by You on research and development for opioids.

RESPONSE NO. 18:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that Topic No. 18 is an interrogatory-style topic. Janssen further objects that the topic is overly broad and unduly burdensome. Subject to and without waiving the foregoing objections, Janssen proposes to provide a written response to this topic regarding the amount spent by Janssen on research and development relating to Janssen's Opioid Products, in lieu of deposition testimony. Janssen will make itself available to meet and confer with regard to this proposal.

TOPIC NO. 19:

Your educational and/or research grants provided by You to individuals or entities regarding opioids and/or pain treatment.

RESPONSE NO. 19:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that Topic No. 19 is an interrogatory-style topic. Janssen further objects that the topic is overly broad and unduly burdensome. Subject to and without waiving the foregoing objections, Janssen proposes to provide a written response to this topic regarding the amount spent by Janssen on educational and/or research grants provided to third parties related to opioids and/or pain treatment, in lieu of deposition testimony. Janssen will make itself available to meet and confer with regard to this proposal.

TOPIC NO. 20:

Your actions and/or efforts in response to the FDA's September 10, 2013 response to the PROP Petition from July 25, 2012.

RESPONSE NO. 20:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that the topic is overly broad, unduly burdensome, and fails to describe with reasonable particularity the matters to be examined. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information about any Janssen response to the FDA's September 10, 2013 response to the PROP Petition from July 25, 2012.

TOPIC NO. 21:

Your role, influence, or support for any campaign or movement to declare pain as the "Fifth Vital Sign."

RESPONSE NO. 21:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that the topic seeks information that is unrelated to the claims and defenses in this litigation,

is overly broad and unduly burdensome, and fails to describe with reasonable particularity the matters for examination. Janssen further objects that "influence," "campaign," or "movement" is vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information concerning any Janssen efforts related to the "Fifth Vital Sign" in Oklahoma (to the extent any national activities extended to Oklahoma, they will be included).

TOPIC NO. 22:

Your interactions and communications with medical schools in Oklahoma, including without limitation, financial contributions, speeches, presentations, scholarships, event sponsorship, research grants, educational materials, and/or branded promotional materials.

RESPONSE NO. 22:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that Topic No. 22 is an interrogatory-style topic. Janssen further objects that the topic is overly broad and unduly burdensome. Subject to and without waiving the foregoing objections, Janssen proposes to provide a written response to this topic regarding interactions and communications with medical schools in Oklahoma related to Janssen's Opioid Products, in lieu of deposition testimony. Janssen will make itself available to meet and confer with regard to this proposal.

TOPIC NO. 23:

Your use of public relations firms and communication with journalists regarding opioids and/or pain management marketing, including without limitation, the American Enterprise Institute, Cancer Action Network, Center for Lawful Access & Abuse Deterrence, Pinney Associates, Conrad & Associates LLC, and Sense About Science USA.

RESPONSE NO. 23:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that Topic No. 23 is an interrogatory-style topic. Janssen further objects that the topic is overly broad and unduly burdensome. Subject to and without waiving the foregoing objections, Janssen proposes to provide a written response to this topic regarding communications with journalists related to Janssen's Opioid Products, in lieu of deposition testimony. Janssen will make itself available to meet and confer with regard to this proposal.

TOPIC NO. 24:

The amount of revenue and profits earned by You attributable to and/or derived from the prescription of opioids by any Oklahoma doctor criminally investigated, charged, indicted, and/or prosecuted for prescribing practices related to opioids. For purposes of this topic, "prosecution" includes any administrative proceeding.

RESPONSE NO. 24:

Janssen objects to this topic on the grounds set forth in its General Objections. The topic is overly broad and unduly burdensome to the extent Janssen does not have this information available and cannot identify every doctor in Oklahoma that has been "criminally investigated, charged, indicated and/or prosecuted," particularly in light of Plaintiff's refusal to produce documents that would allegedly jeopardize criminal investigations. Janssen further objects that this topic fails to describe with reasonable particularity the matters for examination. Janssen also objects that "attributed to," "derived from," and "prescribing practices" are vague and ambiguous.

TOPIC NO. 25:

Your use of medical education communication companies (MECCs) regarding opioids and/or pain management marketing.

RESPONSE NO. 25:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects to the extent that the topic seeks information that is unrelated to the claims and defenses in this litigation. The topic is overly broad and unduly burdensome. Janssen further objects that "use" is vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information about Janssen's processes to distribute marketing communications regarding Janssen's Opioid Products in Oklahoma.

TOPIC NO. 26:

Your use of speakers' bureaus, advisory boards, or other similar programs regarding opioids and/or pain management marketing.

RESPONSE NO. 26:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects to the extent that the topic seeks information that is unrelated to the claims and defenses in this litigation. The topic is overly broad and unduly burdensome. Janssen further objects that "use" and "similar programs" are vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information about Janssen's use of speakers' bureaus regarding Janssen's Opioid Products in Oklahoma.

TOPIC NO. 27:

Your use of medical liaisons to communicate with Healthcare Professionals, KOLs, and/or Front Groups regarding opioids and/or pain treatment.

RESPONSE NO. 27:

Janssen objects to this topic on the grounds set forth in its General Objections. The topic is overly broad, unduly burdensome, and fails to describe with reasonable particularity the matters to be examined. Janssen also objects to the term "Front Groups" as vague and ambiguous. Janssen further objects to this term on the grounds that it is inappropriately pejorative and inaccurately represents Janssen's relationships with independent third-party organizations. Janssen further objects to the use of the term "Front Groups" because it is overly broad and unduly burdens Janssen to the extent that it includes organizations that did not make any alleged representations regarding Janssen's Opioid Products to Oklahoma patients or prescribers. Janssen further objects to the term "KOLs" on the grounds that it is vague and ambiguous. This term seeks information irrelevant to the case, is overly broad, and imposes undue burden and expense on Defendants in relation to the needs of the case to the extent that the term includes individuals who did not make any alleged representations regarding Janssen's Opioid Products to Oklahoma patients or prescribers. Janssen also objects that "use" is vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information about Janssen's use of medical liaisons to communicate with healthcare providers or organizations identified in Plaintiff's Complaint concerning Janssen's Opioid Products and/or pain treatment.

TOPIC NO. 28:

Your use of data provided by IMS, IQVIA or any similar data service for purposes of marketing and/or sales strategies.

RESPONSE NO. 28:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that this topic is overly broad, unduly burdensome, and fails to describe with reasonable particularity the matters to be examined. Janssen further objects that "use" and "similar data service" are vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information about data used by Janssen for its marketing and sales activities for Janssen's Opioid Products.

TOPIC NO. 29:

Your use of clinical trial companies regarding opioids and/or pain management.

RESPONSE NO. 29:

Janssen objects to this topic on the grounds set forth in its General Objections. To the extent that Janssen has already provided documentary discovery responses related to Topic 29, Janssen objects. Further, this topic is overly broad and unduly burdensome. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information about the clinical trial companies Janssen used for its studies submitted to the FDA in conjunction with the IND/NDAs of Janssen's Opioid Products.

TOPIC NO. 30:

Clinical trials funded, sponsored, and/or conducted by You regarding opioids and/or pain management.

RESPONSE NO. 30:

Janssen objects to this topic on the grounds set forth in its General Objections. To the extent that Janssen has already provided documentary discovery responses related to Topic 29, Janssen objects. Janssen also objects to the extent that Topic 29 calls for information within the purview of expert testimony. Further, this topic is overly broad and unduly burdensome. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information about Janssen's studies, scientific research, tests, trials or analysis of the safety and efficacy that Janssen submitted to the FDA in conjunction with the IND/NDAs of Janssen's Opioid Products.

TOPIC NO. 31:

Your sales projections and/or research related to the amount of reimbursement for Your opioids prescriptions that would be paid by Medicare and/or Oklahoma's Medicaid Program.

RESPONSE NO. 31:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that Topic No. 31 seeks information that is overly broad and unduly burdensome. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information concerning Janssen's sales projections or research regarding reimbursements related to Janssen's Opioid Products in Oklahoma.

TOPIC NO. 32:

Your efforts and actions, both internally and in conjunction with third parties, to obtain and/or increase coverage and/or reimbursement of their opioids by public payers, including SoonerCare.

RESPONSE NO. 32:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that Topic No. 32 seeks information that is unrelated to the claims and defenses in this litigation and is overly broad and unduly burdensome. Janssen further objects that "in conjunction with third parties" is vague and ambiguous. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information concerning Janssen's actions related to the coverage and/or reimbursement of Janssen's Opioid Products by public payers in Oklahoma.

TOPIC NO. 33:

Your relationship and business dealings with other opioid manufacturers related to opioids and/or pain management, including without limitations any co-promotion or ownership agreements.

RESPONSE NO. 33:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that the topic seeks information that is unrelated to the claims and defenses in this litigation, is overly broad and unduly burdensome, and fails to describe with reasonable particularity the matters for examination. Janssen further objects that "relationship" and "business dealings" are vague and ambiguous. Janssen further objects to the extent that the topic seeks information protected by the attorney-client, joint defense, or common interest privilege. Subject to and without waiving these

objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information regarding business dealings, if any, with the other Defendants in this matter.

TOPIC NO. 34:

The source of ingredients, compounds or components, such as Thebaine (CPS-T), utilized by You in the manufacture of any opioids sold by You in the United States, including without limitation the amount of money paid to purchase such opioid compounds or components and U.S. distribution and sale of CPS-T.

RESPONSE NO. 34:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that Topic No. 34 is an interrogatory-style topic. Janssen further objects that Topic No. 34 seeks information that is unrelated to the claims and defenses in this litigation and is overly broad and unduly burdensome. Subject to and without waiving the foregoing objections, Janssen proposes to provide a written response to this topic in lieu of deposition testimony. Janssen will make itself available to meet and confer with regard to this proposal.

TOPIC NO. 35:

All opioids manufactured, owned, contemplated, developed, and/or in-development by You including the nature of each such opioid, its intended use, and the stage of development of each (e.g. released to market, in development, abandoned).

RESPONSE NO. 35:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that Topic No. 35 is an interrogatory-style topic. Janssen further objects that "contemplated" and "in-development" are vague and ambiguous. Janssen further objects that information on all opioids "contemplated" or "in-development" by Janssen is confidential, proprietary, and unrelated to the claims and defenses in this litigation, and that providing such

information would be unduly burdensome. Subject to and without waiving the foregoing objections, Janssen proposes to provide a written response to this topic regarding opioids manufactured, owned, and/or developed by Janssen, in lieu of deposition testimony. Janssen will make itself available to meet and confer with regard to this proposal.

TOPIC NO. 36:

All drugs for opioid use disorder manufactured, owned, contemplated, developed, and/or in-development by You including the nature of each such opioid use disorder drug, its intended use, the stage of development of each (e.g. released to market, in development, abandoned), and profits earned by You from the sale of any such drug in Oklahoma.

RESPONSE NO. 36:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that Topic No. 36 is an interrogatory-style topic. Janssen further objects that "contemplated" and "in-development" are vague and ambiguous. Janssen further objects that information on all drugs for opioid use disorder "contemplated" or "in-development" by Janssen is confidential, proprietary, and unrelated to the claims and defenses in this litigation, and that providing such information would be unduly burdensome. Subject to and without waiving the foregoing objections, Janssen proposes to provide a written response to this topic regarding drugs for opioid use disorder manufactured, owned, and/or developed by Janssen, if any, in lieu of deposition testimony. Janssen will make itself available to meet and confer with regard to this proposal.

TOPIC NO. 37:

All drugs for the treatment of opioid overdose manufactured, owned, contemplated, developed, and/or in-development by You including the nature of each such opioid overdose

drug, its intended use, the stage of development of each (e.g. released to market, in development, abandoned), and profits earned by You from the sale of any such drug in Oklahoma.

RESPONSE NO. 37:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that Topic No. 37 is an interrogatory-style topic. Janssen further objects that "contemplated" and "in-development" are vague and ambiguous. Janssen further objects that information on all drugs for the treatment of opioid overdose "contemplated" or "in-development" by Janssen is confidential, proprietary, and unrelated to the claims and defenses in this litigation, and that providing such information would be unduly burdensome. Subject to and without waiving the foregoing objections, Janssen proposes to provide a written response to this topic regarding drugs for the treatment of opioid overdose manufactured, owned, and/or developed by Janssen, if any, in lieu of deposition testimony. Janssen will make itself available to meet and confer with regard to this proposal.

TOPIC NO. 38:

Policies, practices, and procedures regarding complaints You received related to addiction or abuse of Your opioids in Oklahoma.

RESPONSE NO. 38:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects to the extent that Topic No. 38 seeks information that is unrelated to the claims and defenses in this litigation or calls for information in the purview of expert testimony. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information about Janssen's policies and procedures regarding

reports or complaints of abuse, misuse, dependence, or addiction potential for Janssen's Opioid Products.

TOPIC NO. 39:

Your involvement in the Pain Care Forum.

RESPONSE NO. 39:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that the topic seeks information that is unrelated to the claims and defenses in this litigation, is overly broad and unduly burdensome, and fails to describe with reasonable particularity the matters for examination. Subject to and without waiving these objections, Janssen will designate a witness to testify generally about any Janssen involvement in the Pain Care Forum.

TOPIC NO. 40:

The factual bases supporting Your defenses to Plaintiff's claims as set forth in Your Answer.

RESPONSE NO. 40:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that the topic fails to describe with reasonable particularity the matters for examination. Janssen further objects that this topic seeks information that is protected from disclosure by the attorney-client privilege, work product doctrine, joint defense privilege, and common interest privilege. Janssen further objects that this topic is overly broad and unduly burdensome, is therefore improper, and it would be impossible to designate a witness on all facts in this case.

TOPIC NO. 41:

Your efforts or activities in Oklahoma concerning opioids related to: (a) lobbying efforts; (b) campaign contributions; (c) presentations made to the Oklahoma Health Care Authority's Drug Utilization Review Board; (d) scheduling of opioids; (e) opposing the rescheduling hydrocodone combination products from Schedule III to Schedule II; (f) pain management guidelines in Oklahoma statutes; (g) legislative efforts or activities; (h) law enforcement; and (i) prosecution of any individual or entity related to use, misuse, abuse, diversion, supply, and prescription.

RESPONSE NO. 41:

Janssen objects to this topic on the grounds set forth in its General Objections. Janssen also objects that the topic seeks information that is unrelated to the claims and defenses in this litigation, is overly broad and unduly burdensome, and fails to describe with reasonable particularity the matters for examination. Subject to and without waiving these objections, Janssen will designate a witness to testify generally with regard to relevant, nonprivileged information concerning Janssen's lobbying efforts or governmental affairs activities in Oklahoma related to Janssen's Opioid Products.

Dated: September 10, 2018

Respectfully submitted,

By: _____

Benjamin H. Odom, OBA No. 10917
John H. Sparks, OBA No. 15661
Michael W. Ridgeway, OBA No. 15657
David L. Kinney, OBA No. 10875
ODOM, SPARKS & JONES, PLLC
HiPoint Office Building
2500 McGee Drive Ste. 140
Oklahoma City, OK 73072

Telephone: (405) 701-1863
Facsimile: (405) 310-5394
Email: odomb@odomsparks.com
Email: sparksj@odomsparks.com
Email: ridgewaym@odomsparks.com
Email: kinneyd@odomsparks.com

Of Counsel:

Charles C. Lifland
Jennifer D. Cardelús
Wallace Moore Allan
Sabrina H. Strong
O'MELVENY & MYERS, LLP
400 S. Hope Street
Los Angeles, CA 90071
Telephone: (213) 430-6000
Facsimile: (213) 430-6407
Email: clifland@omm.com
Email: jcardelus@omm.com
Email: tallan@omm.com
Email: sstrong@omm.com

Stephen D. Brody
David Roberts
O'MELVENY & MYERS, LLP
1625 Eye Street NW
Washington, DC 20006
Telephone: (202) 383-5300
Facsimile: (202) 383-5414
Email: sbrody@omm.com
Email: droberts2@omm.com

Daniel J. Franklin
O'MELVENY & MYERS, LLP
7 Times Square
New York, NY 10036
Telephone: (212) 326-2000
Facsimile: (212) 326-2061
Email: dfranklin@omm.com

COUNSEL FOR DEFENDANTS JANSSEN PHARMACEUTICALS, INC., JOHNSON & JOHNSON, JANSSEN PHARMACEUTICA, INC. N/K/A JANSSEN PHARMACEUTICALS, INC.,

AND ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. N/K/A/ JANSSEN PHARMACEUTICALS, INC.

CERTIFICATE OF MAILING

Pursuant to Okla. Stat. tit. 12, § 2005(D), this is to certify on September 10th, 2018, a true and correct copy of the above and foregoing has been served via the United States Postal Service, First Class postage prepaid, to the following:

Mike Hunter
ATTORNEY GENERAL FOR
THE STATE OF OKLAHOMA
Abby Dillsaver
Ethan Shaner
GENERAL COUNSEL TO
THE ATTORNEY GENERAL
313 NE 21st
Oklahoma City, OK 73105
Telephone: (405)521-3921
Facsimile: (405) 521-6246
Email: abby.dillsaver@oag.ok.gov
Email: ehtan.shaner@oag.ok.gov

Michael Burrage
Reggie Whitten
WHITTEN BURRAGE
Suite 300
512 North Broadway Avenue
Oklahoma City, OK 73102
Telephone: (405) 516-7800
Facsimile: (405) 516-7859
Email: mburrage@whittenburragelaw.com
Email: rwhitten@whittenburragelaw.com

Bradley Beckworth
Jeffrey Angelovich
Lloyd Nolan Duck, III
Andrew Pate
Lisa Baldwin
NIX, PATTERSON & ROACH, LLP
Suite 200
512 North Broadway Avenue
Oklahoma City, OK 73102
Telephone: (405) 516-7800
Facsimile: (405) 516-7859
Email: bbeckworth@nixlaw.com
Email: jangelovich@nixlaw.com
Email: tduck@nixlaw.com
Email: dpate@nixlaw.com

Email: lbaldwin@nixlaw.com

Glenn Coffee
GLENN COFFEE & ASSOCIATES, PLLC
915 North Robinson Avenue
Oklahoma City, OK 73102
Telephone: (405) 601-1616
Email: gcoffee@glenncoffe.com

ATTORNEYS FOR PLAINTIFF

Sanford C. Coats
Joshua D. Burns
CROWE & DUNLEVY, PC
Suite 100
Braniff Building
324 North Robinson Avenue
Oklahoma City, OK 73102
Telephone: (405) 235-7700
Facsimile: (405) 272-5269
Email:sandy.coats@crowedunlevy.com
Email:joshua.burns@crowedunlevy.com

Of Counsel:

Sheila Birnbaum
Mark S. Cheffo
Hayden A. Coleman
Paul A. LaFata
Jonathan S. Tam
DECHERT, LLP
Three Bryant Park
1095 Avenue of Americas
New York, NY 10036-6797
Telephone: (212) 698-3500
Facsimile: (212) 698-3599
Email:sheila.birnbaum@dechert.com
Email:mark.cheffo@dechert.com
Email:hayden.colemand@dechert.com
Email:paul.lafata@dechert.com
Email:jonathan.tam@dechert.com

Robert S. Hoff
WIGGIN & DANA, LLP
265 Church Street
New Haven, CT 06510
Telephone: (203) 498-4400
Facsimile: (203) 363-7676
Email: rhoff@wiggin.com

ATTORNEYS FOR DEFENDANTS PURDUE PHARMA, LP, PURDUE PHARMA, INC., AND THE PURDUE FREDERICK COMPANY, INC.

Robert G. McCampbell
Travis V. Jett
Ashley E. Quinn
Nicholas V. Merkley
GABLEGOTWALS
15th Floor
One Leadership Square
211 North Robinson
Oklahoma City, OK 73102-7255
Telephone: (405) 235-5567
Email: rmccampbell@gablelaw.com
Email: tjett@gablelaw.com
Email: aquinn@gablelaw.com
Email: nmerkley@gablelaw.com

Of Counsel:

Steven A. Reed
Harvey Bartle, IV
Rebecca J. Hillyer
Lindsey T. Mills
MORGAN, LEWIS & BOCKIUS, LLP
1701 Market Street
Philadelphia, PA 19103-2321
Telephone: (215) 963-5000
Email: steven.reed@morganlewis.com
Email: harvey.bartle@morganlewis.com
Email: rebecca.hillyer@morganlewis.com
Email: lindsey.mills@morganlewis.com

Brian M. Ercole
MORGAN, LEWIS & BOCKIUS, LLP
Suite 5300
200 South Biscayne Boulevard
Miami, FL 33131
Email: brian.ercole@morganlewis.com

ATTORNEYS FOR DEFENDANTS CEPHALON, INC., TECA PHARMACEUTICALS USA, INC., WATSON LABORATORIES, INC., ACTAVIS, LLC, AND ACTAVIS PHARMA, INC. F/K/A WATSON PHARMA, INC.



Benjamin H. Odom

EXHIBIT C

From: Drew Pate <dpate@nixlaw.com>
Sent: Monday, October 29, 2018 4:28 PM
To: Brody, Steve <sbrody@omm.com>; Roberts, David K. (DC) <droberts2@omm.com>; Baglin, Seth <sbaglin@omm.com>
Cc: Brad Beckworth <bbeckworth@nixlaw.com>; Trey Duck <tduck@nixlaw.com>; Lisa Baldwin <lbaldwin@nixlaw.com>; Ross Leonoudakis <rossl@nixlaw.com>; Winn Cutler <winncutler@nixlaw.com>; mburrage@whittenburragelaw.com; rwhitten@whittenburragelaw.com; Amanda Thompson <athompson@nixlaw.com>; cnorman@whittenburragelaw.com; odomb@odomsparks.com; sparksj@odomsparks.com
Subject: Oklahoma v Purdue Pharma et al - Deposition Topics

Steve,

Pursuant to Judge Hetherington's Order, we are providing this information regarding the corporate representative deposition topics the State has requested from Janssen.

Janssen has been in possession of the list of the vast majority of deposition topics we have requested since April.

In the interest of efficiency, we have narrowed the deposition topics that we are currently seeking. Specifically, we have removed Topic Nos. 13, 19, 20, and 29 (as previously numbered and as indicated on the attached).

Further, with respect to Topic Nos. 24, 30, 31, 34, 42, and 43 we are open to narrowing those topics by receiving a written response and can discuss further about what the response should include. In the meantime, let's proceed with scheduling the depositions knowing that we may be able to narrow them or not take them depending on the scope of the written response provided.

Finally, in the interest of efficiency, I've re-attached our suggested deposition grouping because we believe it will save the parties time and travel to address the topics that fit together in these ways.

We are still proceeding on November 9th as planned regarding Topic Nos. 39 and 41.

Best regards,

Drew

Drew Pate

NIX PATTERSON, LLP

3600 N. Capital of Texas Hwy.
Building B, Suite 350
Austin, TX 78746
512-328-5333
Dpate@nixlaw.com

Category	Topic Descriptions	Hours Needed
1	TOPIC 21: Your role, influence, or support for any campaign or movement to declare pain as the "Fifth Vital Sign." TOPIC 1: Your involvement with, and contributions to, non-profit organizations and professional societies, including the Front Groups.	6
2	TOPIC 2: Your involvement with, and contributions to, KOLs regarding opioids and/or pain treatment.	6
3	TOPIC 23: Your use of public relations firms and communication with journalists regarding opioids and/or pain management marketing, including without limitation, the American Enterprise Institute, Cancer Action Network, Center for Lawful Access & Abuse Deterrence, Pinney Associates, Conrad & Associates LLC, and Sense About Science USA. TOPIC 5: Your use of continuing medical education regarding opioids nationally and in Oklahoma, including the scope, strategy, purpose and goals with respect to such continuing medical education. TOPIC 17: Amounts spent by You on advertising and marketing related to opioids.	6
3	TOPIC 3: Your use of branded marketing for opioids nationally and in Oklahoma, including the scope, strategy, purpose and goals with respect to such branded marketing. TOPIC 4: Your use of unbranded marketing for opioids nationally and in Oklahoma, including the scope, strategy, purpose and goals with respect to such unbranded marketing.	6
4	TOPIC 27: Your use of medical liaisons to communicate with Healthcare Professionals, KOLs, and/or Front Groups regarding opioids and/or pain treatment. TOPIC 10: The scope, strategy, purpose, and goals for Your opioids sales forces, including without limitation: training policies and practices; sales tactics; compensation structures; incentive programs; award programs; sales quotas; methods for assigning sales representatives to particular regions; facilities and/or physicians; and Your use of such sales forces in Oklahoma.	6

5	TOPIC 11: Your practices and processes for identifying and prioritizing physicians to detail. TOPIC 12: Your research of Oklahoma Healthcare Professionals' and/or pharmacies' opioid prescribing habits, history, trends, sales, practices and/or abuse and diversion of opioids. TOPIC 14: Your use of 'do not call' lists or any similar list of prescribers that your sales representatives do not contact. TOPIC 15: Your efforts to identify high-prescribing health care providers in the State of Oklahoma. TOPIC 16: Your efforts to identify low-prescribing health care providers in the State of Oklahoma.	6
6	TOPIC 22: Your interactions and communications with medical schools in Oklahoma, including without limitation, financial contributions, speeches, presentations, scholarships, event sponsorship, research grants, educational materials, and/or branded promotional materials. TOPIC 25: Your use of medical education communication companies (MECCs) regarding opioids and/or pain management marketing. TOPIC 26: Your use of speakers' bureaus, advisory boards, or other similar programs regarding opioids and/or pain management marketing.	6
7	TOPIC 28: Your use of data provided by IMS, IQVIA or any similar data service for purposes of marketing and/or sales strategies. TOPIC 31: Your sales projections and/or research related to the amount of reimbursement for Your opioids prescriptions that would be paid by Medicare and/or Oklahoma's Medicaid Program. TOPIC 32: Your efforts and actions, both internally and in conjunction with third parties, to obtain and/or increase coverage and/or reimbursement of their opioids by public payers, including SoonerCare.	6
8	TOPIC 20: Your actions and/or efforts in response to the FDA's September 10, 2013 response to the PROP Petition from July 25, 2012. TOPIC 29: Your use of clinical trial companies regarding opioids and/or pain management. TOPIC 30: Clinical trials funded, sponsored, and/or conducted by You regarding opioids and/or pain management. TOPIC 8. Your research conducted, funded, directed and/or influenced, in whole or in part, related to pseudoaddiction.	6

8	TOPIC 6: Research conducted, funded, directed and/or influenced by You, in whole or in part, related to opioid risks and/or efficacy. TOPIC 19. Your educational and/or research grants provided by You to individuals or entities regarding opioids and/or pain treatment. TOPIC 18: Amounts spent by You on research and development for opioids	6
9	TOPIC 7: Your scientific support for Your marketing statements and representations regarding the risks and benefits of opioids. TOPIC 9: Your scientific support for Your marketing statements and representations regarding pseudoaddiction.	6
10	TOPIC 40: The factual bases supporting Your defenses to Plaintiff's claims as set forth in Your Answer.	6
11	TOPIC 39: Your involvement and participation in the Pain Care Forum. TOPIC 41: LOBBYING EFFORTS - Your efforts or activities in Oklahoma concerning opioids related to: (a) lobbying efforts; (b) campaign contributions; (c) presentations made to the Oklahoma Health Care Authority's Drug Utilization Review Board; (d) scheduling of opioids; (e) opposing the rescheduling hydrocodone combination products from Schedule III to Schedule II; (f) pain management guidelines in Oklahoma statutes; (g) legislative efforts or activities; (h) law enforcement; and (i) prosecution of any individual or entity related to use, misuse, abuse, diversion, supply, and prescription.	6
12	TOPIC 38: Policies, practices, and procedures regarding complaints You received related to addiction or abuse of Your opioids in Oklahoma. TOPIC 13. Your use and/or establishment of any opioid abuse and diversion program You established and implemented to identify Healthcare Professionals' and/or pharmacies' potential abuse or diversion of opioids.	6
13	TOPIC 33: Your relationship and business dealings with other opioid manufacturers related to opioids and/or pain management, including without limitations any co-promotion or ownership agreements. TOPIC 34: The source of ingredients, compounds or components, such as Thebaine (CPS-T), utilized by You in the manufacture of any opioids sold by You in the United States, including without limitation the amount of money paid to purchase such opioid compounds or components and U.S. distribution and sale of CPS-T.	6

14	TOPIC 35: All opioids manufactured, owned, contemplated, developed, and/or in-development by You including the nature of each such opioid, its intended use, and the stage of development of each (e.g. released to market, in development, abandoned). TOPIC 36: All drugs for opioid use disorder manufactured, owned, contemplated, developed, and/or in-development by You including the nature of each such opioid use disorder drug, its intended use, the stage of development of each (e.g. released to market, in development, abandoned), and profits earned by You from the sale of any such drug in Oklahoma. TOPIC 37: All drugs for the treatment of opioid overdose manufactured, owned, contemplated, developed, and/or in-development by You including the nature of each such opioid overdose drug, its intended use, the stage of development of each (e.g. released to market, in development, abandoned), and profits earned by You from the sale of any such drug in Oklahoma.	6
15	TOPIC 24: The amount of revenue and profits earned by You attributable to and/or derived from the prescription of opioids by any Oklahoma doctor criminally investigated, charged, indicted, and/or prosecuted for prescribing practices related to opioids. For purposes of this topic, "prosecution" includes any administrative proceeding.	6

Topic No.	Topic Description
1	Your involvement with, and contributions to, non-profit organizations and professional societies, including the Front Groups.
2	Your involvement with, and contributions to, KOLs regarding opioids and/or pain treatment.
3	Your use of branded marketing for opioids nationally and in Oklahoma, including the scope, strategy, purpose and goals with respect to such branded marketing.
4	Your use of unbranded marketing for opioids nationally and in Oklahoma, including the scope, strategy, purpose and goals with respect to such unbranded marketing.
5	Your use of continuing medical education regarding opioids nationally and in Oklahoma, including the scope, strategy, purpose and goals with respect to such continuing medical education.
6	Research conducted, funded, directed and/or influenced by You, in whole or in part, related to opioid risks and/or efficacy.
7	Your scientific support for Your marketing statements and representations regarding the risks and benefits of opioids.
8	Your research conducted, funded, directed and/or influenced, in whole or in part, related to pseudoaddiction.
9	Your scientific support for Your marketing statements and representations regarding pseudoaddiction.

10	The scope, strategy, purpose, and goals for Your opioids sales forces, including without limitation: training policies and practices; sales tactics; compensation structures; incentive programs; award programs; sales quotas; methods for assigning sales representatives to particular regions; facilities and/or physicians; and Your use of such sales forces in Oklahoma.
11	Your practices and processes for identifying and prioritizing physicians to detail.
12	Your research of Oklahoma Healthcare Professionals' and/or pharmacies' opioid prescribing habits, history, trends, sales, practices and/or abuse and diversion of opioids.
~~13~~	~~Your use and/or establishment of any opioid abuse and diversion program You established and implemented to identify Healthcare Professionals' and/or pharmacies' potential abuse or diversion of opioids.~~
14	Your use of 'do not call' lists or any similar list of prescribers that your sales representatives do not contact.
15	Your efforts to identify high-prescribing health care providers in the State of Oklahoma.
16	Your efforts to identify low-prescribing health care providers in the State of Oklahoma.
17	Amounts spent by You on advertising and marketing related to opioids.
18	Amounts spent by You on research and development for opioids.
~~19~~	~~Your educational and/or research grants provided by You to individuals or entities regarding opioids and/or pain treatment.~~

~~20~~	~~Your actions and/or efforts in response to the FDA's September 10, 2013 response to the PROP Petition from July 25, 2012.~~
21	Your role, influence, or support for any campaign or movement to declare pain as the "Fifth Vital Sign."
22	Your interactions and communications with medical schools in Oklahoma, including without limitation, financial contributions, speeches, presentations, scholarships, event sponsorship, research grants, educational materials, and/or branded promotional materials.
23	Your use of public relations firms and communication with journalists regarding opioids and/or pain management marketing, including without limitation, the American Enterprise Institute, Cancer Action Network, Center for Lawful Access & Abuse Deterrence, Pinney Associates, Conrad & Associates LLC, and Sense About Science USA.
24	The amount of revenue and profits earned by You attributable to and/or derived from the prescription of opioids by any Oklahoma doctor criminally investigated, charged, indicted, and/or prosecuted for prescribing practices related to opioids. For purposes of this topic, "prosecution" includes any administrative proceeding.*
25	Your use of medical education communication companies (MECCs) regarding opioids and/or pain management marketing.
26	Your use of speakers' bureaus, advisory boards, or other similar programs regarding opioids and/or pain management marketing.
27	Your use of medical liaisons to communicate with Healthcare Professionals, KOLs, and/or Front Groups regarding opioids and/or pain treatment.

28	Your use of data provided by IMS, IQVIA or any similar data service for purposes of marketing and/or sales strategies.
~~29~~	~~Your use of clinical trial companies regarding opioids and/or pain management.~~
30	Clinical trials funded, sponsored, and/or conducted by You regarding opioids and/or pain management.*
31	Your sales projections and/or research related to the amount of reimbursement for Your opioids prescriptions that would be paid by Medicare and/or Oklahoma's Medicaid Program.*
32	Your efforts and actions, both internally and in conjunction with third parties, to obtain and/or increase coverage and/or reimbursement of their opioids by public payers, including SoonerCare.
33	Your relationship and business dealings with other opioid manufacturers related to opioids and/or pain management, including without limitations any co-promotion or ownership agreements.
34	The source of ingredients, compounds or components, such as Thebaine (CPS-T), utilized by You in the manufacture of any opioids sold by You in the United States, including without limitation the amount of money paid to purchase such opioid compounds or components and U.S. distribution and sale of CPS-T.*
35	All opioids manufactured, owned, contemplated, developed, and/or in-development by You including the nature of each such opioid, its intended use, and the stage of development of each (e.g. released to market, in development, abandoned).

36	All drugs for opioid use disorder manufactured, owned, contemplated, developed, and/or in-development by You including the nature of each such opioid use disorder drug, its intended use, the stage of development of each (e.g. released to market, in development, abandoned), and profits earned by You from the sale of any such drug in Oklahoma.
37	All drugs for the treatment of opioid overdose manufactured, owned, contemplated, developed, and/or in-development by You including the nature of each such opioid overdose drug, its intended use, the stage of development of each (e.g. released to market, in development, abandoned), and profits earned by You from the sale of any such drug in Oklahoma.
38	Policies, practices, and procedures regarding complaints You received related to addiction or abuse of Your opioids in Oklahoma.
39	Your involvement and participation in the Pain Care Forum.
40	The factual bases supporting Your defenses to Plaintiff's claims as set forth in Your Answer.
41	Your efforts or activities in Oklahoma concerning opioids related to: (a) lobbying efforts; (b) campaign contributions; (c) presentations made to the Oklahoma Health Care Authority's Drug Utilization Review Board; (d) scheduling of opioids; (e) opposing the rescheduling hydrocodone combination products from Schedule III to Schedule II; (f) pain management guidelines in Oklahoma statutes; (g) legislative efforts or activities; (h) law enforcement; and (i) prosecution of any individual or entity related to use, misuse, abuse, diversion, supply, and prescription.

42	Total compensation paid to employees and contractors who detailed and/or promoted to any health care practitioners and/or pharmacies in Oklahoma, including but not limited to salaries, bonuses, and monetary and non-monetary incentives, and the methodology and metrics used to calculate the compensation paid to those employees and contractors.*
43	Total amount spent annually, including directly and through reimbursement, on all promotional efforts related to Oklahoma and/or nationwide, including but not limited to leave behinds, direct mail materials, journal advertising, speaker engagements, conventions, samples, cards, vouchers, food, drinks, gifts, and swag.*
44	Revenues and profits earned by Noramco from the sale of any opioid APIs during the Relevant Time Period, including revenues and profits earned from transactions with any Defendants, and any contract(s) between any Defendant(s) and Noramco during the Relevant Time Period for the delivery of goods or the performance of services.

EXHIBIT D

O'Melveny & Myers LLP
1625 Eye Street, NW
Washington, DC 20006-4061

T: +1 202 383 5300
F: +1 202 383 5414
omm.com

File Number:
427,892-297

November 9, 2018

Tad Allan
D: +1 213 430 6670
tallan@omm.com

VIA E-MAIL

Drew Pate
NIX PATTERSON LLP
3600 N. Capital of Texas Hwy.
Building B, Suite 350
Austin, TX 78746

Re: *State of Oklahoma v. Purdue Pharma L.P. et al.*, No. CJ-2017-816

Dear Drew:

I am responding to your October 29 letter, as directed by Judge Hetherington's October 22 order, as modified on October 29. First, I note that you have not complied with Judge Hetherington's directive that "State is Ordered to specifically define each topic of requested inquiry and serve on counsel for each Defendant group (or a specific Defendant where a topic is unique to that Defendant) within **five (5)** working days following this Order." What you sent us on October 29 makes no effort to comply with Judge Hetherington's order and instead merely restates your previous proposed grouping of deposition topics. We appreciate, however, your withdrawal of topic nos. 13, 19, 20 and 29.

In our September 9 and October 11 objections, and in a September 24 email, we proposed to respond in writing to certain deposition topics: 17, 18, 22, 23, 35, 36, 37, and 44. On October 29, you informed us that you will accept written responses to topics 24, 30, 31, 34, 42, and 43. Accordingly, Jansen will respond in writing to topics 17, 18, 22, 23, 30, 31, 34, 35, 36, 37, 42, 43, and 44. We stand by our previously served written objections to topics 24 and 40.

We do not agree, however, to your proposal that we respond in writing *and* schedule a witness to testify on these topics. If after receiving our written responses you still wish to conduct a supplemental examination of a corporate representative witness on one or more of these topics, we can meet and confer on your request.

As to topics for which Janssen will provide a witness, Janssen's response to your October 29 letter is as set forth below. Note, however, that although we are proposing specific dates, we are mindful that you may not complete your examination in the allotted time. If additional deposition days are required for any of the corporate representative witnesses following their initial testimony, we will work with you to schedule such dates, subject to the overall limit of 80 hours of testimony for J&J/Janssen family witnesses.

1. As previously agreed, we provided a witness today on topics 39 and 41.

2. We will provide a witness on December 18 and 19 in Princeton, New Jersey, on the following topics: 1, 2, 3, 4, 5, 10, 11, 12, 14, 15, 16, 21, 25, 26, 27, 28, and 32.

3. We will provide a witness on December 20 and 21, also in Princeton, on topics 6, 7, 8 and 9.

4. We will provide another witness in January on topic 33. We will likely assign this topic to one of the fact witnesses you have requested. We will provide you with a proposed date and location soon.

As to your request, received by separate email on October 29, that we schedule thirteen fact witness depositions, it is unfortunate that you elected to formal serve deposition notices this week, a mere nine days after emailing your request to us. It is no simple matter to schedule these depositions, given that some of the witnesses are ex-employees, some are already committed to testify in the MDL cases, and all are affected by the upcoming holiday season. However, we are working diligently to obtain dates and we are able to offer initially Ron Kuntz on December 7, Bruce Moskovitz on December 12, and Roxanne McGregor-Beck on January 16, all in Princeton. We will provide additional dates as soon as we have them.

Sincerely,

Tad Allan

Tad Allan
of O'MELVENY & MYERS LLP

cc: Counsel of Record